TNGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TNGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Tango Therapeutics's current shares buyback ratio was -5.47%.
The historical data trend for Tango Therapeutics's Shares Buyback Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tango Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Shares Buyback Ratio % | - | -0.14 | -0.66 | -15.90 |
Tango Therapeutics Quarterly Data | |||||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Shares Buyback Ratio % | Get a 7-Day Free Trial | -15.13 | -0.35 | -4.43 | -0.29 | -0.35 |
Tango Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Shares Buyback Ratio | = | (Shares Outstanding (EOP) (A: Dec. 2022 ) | - | Shares Outstanding (EOP) (A: Dec. 2023 )) | / | Shares Outstanding (EOP) (A: Dec. 2022 ) |
= | (88.1794 | - | 102.203) | / | 88.1794 | |
= | -15.90% |
Tango Therapeutics's Shares Buyback Ratio for the quarter that ended in Sep. 2024 is calculated as
Shares Buyback Ratio | = | (Shares Outstanding (EOP) (A: Jun. 2024 ) | - | Shares Outstanding (EOP) (A: Sep. 2024 )) | / | Shares Outstanding (EOP) (A: Jun. 2024 ) |
= | (107.044 | - | 107.415) | / | 107.044 | |
= | -0.35% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Tango Therapeutics's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mace Rothenberg | director | 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Third Rock Ventures Iv, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Mva Investors, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Lesley Ann Calhoun | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Douglas Barry | officer: See Remarks | TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142 |
Adam Crystal | officer: See Remarks | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Barbara Weber | director, officer: Chief Executive Officer | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Daniella Beckman | officer: Chief Financial Officer | C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139 |
Boxer Capital, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
John B Ketchum | director | TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215 |
Joseph Lewis | other: See remarks | PO BOX N7776, LYFORD BAHAMAS |
Trv Gp Vi, Llc | director | 201 BROOKLINE AVE., BOSTON MA 02215 |
Third Rock Ventures Gp Vi, L.p. | director | 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215 |
Third Rock Ventures Vi, L.p. | director | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
From GuruFocus
By GuruFocus Research • 03-20-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Business Wire • 04-01-2024
By GuruFocus Research • 02-09-2024
By Business Wire • 11-06-2024
By GuruFocus Research • 02-09-2024
By Business Wire • 08-28-2024
By GuruFocus News • 11-09-2024
By Business Wire • 11-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.